Monoclonal antibodies directed to CD52
The invention provides antibody to canine or feline or equine antigens, e.g., canine CDS2, and methods of making and using antibodies as described.
1. An antibody or antibody fragment recognizing a canine or feline CD52, and comprising a variable domain, wherein the variable domain comprises six CDR regions wherein the CDR regions are independently selected from the CDRs in a sequence selected from SEQ ID NOS: 5-8, wherein the CDR regions are as defined by Kabat, and wherein the antibody or antibody fragment comprises a light chain and a heavy chain and wherein the antibody or antibody fragment further comprises a constant domain which comprises sequences of canine or feline origin.
2. An antibody or antibody fragment according to claim 1 recognizing canine or feline CD52, wherein said variable domain comprises a variable domain from a sequence selected from SEQ ID NOS: 5-8.
3. An antibody or antibody fragment according to claim 1 comprising a variable domain structure selected from AVD-1 through AVD-13.
4. The antibody or antibody fragment according to claim 1 which is a heterochimeric antibody.
5. The antibody or antibody fragment according to claim 1 which binds to canine CD52 and wherein the constant region is of canine origin.
6. The antibody or antibody fragment according to claim 1 which binds to feline CD52 and wherein the constant region is of feline origin.
7. The antibody or antibody fragment according to claim 1 wherein the constant domain comprises a sequence selected for providing enhanced ADCC and/or CDC.
8. A method of treating an animal suffering from a disease or condition characterized by overproliferation of cells expressing CD52 comprising administering an effective amount of an antibody of antibody fragment according to claim 1 .
9. The method of claim 8 wherein the disease or condition is a cancer.
10. The method of claim 8 wherein the disease or condition is an inflammatory disease.
11. The method of claim 8 comprising co-administration of a chemotherapeutic drug, or a second monoclonal antibody.
12. The method of claim 8 wherein the animal is diagnosed as suffering from a disease or condition characterized by overproliferation of cells expressing CD52 using a diagnostic assay comprising an antibody to CD52.
13. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment is an antibody which recognizes a canine CD52, wherein the constant region is of canine origin, and wherein the antibody or antibody fragment comprises SEQ ID NO: 5.
14. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment is an antibody which recognizes a canine CD52, wherein the constant region is of canine origin, and wherein the antibody or antibody fragment comprises SEQ ID NO: 6.
15. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment recognizes a feline CD52, wherein the constant region is of feline origin, and wherein the antibody or antibody fragment comprises SEQ ID NO: 7.
16. A cell line stably expressing the antibody of claim 1 .
17. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment recognizes a feline CD52, wherein the constant region is of feline origin, and wherein the antibody or antibody fragment comprises SEQ ID NO: 8.
18. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment is an antibody which recognizes canine CD52, the antibody comprising a heavy chain comprising SEQ ID NO: 5 and a light chain comprising SEQ ID NO: 6.
19. The antibody or antibody fragment of claim 1 , wherein the antibody or antibody fragment is an antibody which recognizes feline CD52, the antibody comprising a heavy chain comprising SEQ ID NO: 7 and a light chain comprising SEQ ID NO: 8.